The combination of strong revenue growth, significant margin expansion from royalty reductions, and solid cash generation makes CPRX a compelling growth story. Traders should monitor the execution of 2026 guidance and the outcome of the remaining FIRDAPSE patent litigation with Hetero USA.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $24.88entry
- T+1 · 9mo ago −7.23%α −6.78% · $23.08
- T+5 · 9mo ago −2.25%α −1.12% · $24.32
- T+20 · 8mo ago −2.53%α +3.87% · $24.25
- T+60 · 6mo ago +25.72%α +17.97% · $31.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals reported record financial results for Q4 and full year 2025, with total revenues of $589.0 million (up 19.8% YoY) and GAAP net income of $214.3 million (up 30.8% YoY), driven by strong growth in FIRDAPSE and AGAMREE. The company provided 2026 revenue guidance of $615–645 million and announced favorable royalty changes for FIRDAPSE that will improve margins starting in 2026.
Key Facts
- Full year 2025 total revenues were $589.0 million, up 19.8% YoY
- GAAP net income was $214.3 million, up 30.8% YoY
- Q4 2025 revenues were $152.6 million, up 7.6% YoY
- FIRDAPSE net revenue grew 17.1% YoY to $358.4 million in 2025
- AGAMREE net revenue grew 154.3% YoY to $117.1 million in 2025
- 2026 revenue guidance set at $615–645 million (up 11.1–16.4% from 2025)
- FIRDAPSE royalty rate will drop from 18.5% to 6% starting January 26, 2026, significantly improving margins
- Cash and cash equivalents increased 37% to $709.2 million as of December 31, 2025
Financial Impact
2026 revenue guidance of $615–645 million implies 11.1–16.4% growth; FIRDAPSE royalty reduction from 18.5% to 6% will significantly improve gross margins and profitability starting in 2026
Risk Factors
- Remaining patent litigation with Hetero USA, Inc. scheduled for trial on March 23, 2026
- Decline in FYCOMPA revenue due to generic competition (down 17.4% in 2025)
- Execution risk on business development strategy and potential acquisitions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-071702 |
| Document: d108222d8k.htm | 0001193125-26-071702 |
| Document: 0001193125-26-071702-index-headers.html | 0001193125-26-071702 |
| Document: 0001193125-26-071702-index.html | 0001193125-26-071702 |
| Document: 0001193125-26-071702.txt | 0001193125-26-071702 |
Track record
16 reports on CPRX
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +0.74% at T+20 after the May 28, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers